# PERL Continuous Glucose Monitoring (CGM) Study

> **NCT03334318** · — · COMPLETED · sponsor: **Joslin Diabetes Center** · enrollment: 175 (actual)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **OTHER:** Mean blood glucose
- **OTHER:** Blood glucose CV
- **OTHER:** % time 70-180 mg/dL
- **OTHER:** % time below 54 mg/dL
- **OTHER:** % time above 180 mg/dL
- **OTHER:** % time above 250 mg/dL
- **OTHER:** MAGE (Mean amplitude of glucose excursions)
- **OTHER:** LBGI (Low Blood Glucose Index)
- **OTHER:** HBGI (High Blood Glucose Index)
- **DRUG:** Allopurinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03334318
- **Lead sponsor:** Joslin Diabetes Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2019-08-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2022-03-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334318, "PERL Continuous Glucose Monitoring (CGM) Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03334318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*